ACE and chronic kidney disease: Inhibition of the renin-angiotensin-aldosterone system with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) delays CKD progression in patients with or without diabetes and stage 1–3 CKD, and also in patients without diabetes with stage 4 CKD [7–12].